ZA88488B - Hepatitis b virus surface antigens and hybrid antigens containing them - Google Patents

Hepatitis b virus surface antigens and hybrid antigens containing them

Info

Publication number
ZA88488B
ZA88488B ZA88488A ZA88488A ZA88488B ZA 88488 B ZA88488 B ZA 88488B ZA 88488 A ZA88488 A ZA 88488A ZA 88488 A ZA88488 A ZA 88488A ZA 88488 B ZA88488 B ZA 88488B
Authority
ZA
South Africa
Prior art keywords
antigens
hepatitis
hybrid
virus surface
surface antigens
Prior art date
Application number
ZA88488A
Other languages
English (en)
Inventor
Teresa Cabezon
Cabezon Teresa
Michel De Wilde
De Wilde Michel
Nigel Harford
Harford Nigel
Original Assignee
Smith Kline Rit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline Rit filed Critical Smith Kline Rit
Publication of ZA88488B publication Critical patent/ZA88488B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/78—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
ZA88488A 1987-01-30 1988-01-25 Hepatitis b virus surface antigens and hybrid antigens containing them ZA88488B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US932587A 1987-01-30 1987-01-30

Publications (1)

Publication Number Publication Date
ZA88488B true ZA88488B (en) 1988-10-26

Family

ID=21736956

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA88488A ZA88488B (en) 1987-01-30 1988-01-25 Hepatitis b virus surface antigens and hybrid antigens containing them

Country Status (20)

Country Link
EP (1) EP0278940A3 (fr)
JP (1) JPS6463382A (fr)
KR (1) KR880009130A (fr)
CN (1) CN1031395A (fr)
AP (1) AP56A (fr)
AU (1) AU1093088A (fr)
DD (3) DD285612A5 (fr)
DK (1) DK43188A (fr)
FI (1) FI880428A (fr)
HU (1) HUT50876A (fr)
IL (1) IL85216A0 (fr)
MA (1) MA21169A1 (fr)
NO (1) NO880395L (fr)
NZ (1) NZ223297A (fr)
OA (1) OA08801A (fr)
PT (1) PT86640B (fr)
SU (1) SU1746887A3 (fr)
TN (1) TNSN88004A1 (fr)
YU (1) YU17488A (fr)
ZA (1) ZA88488B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE207535T1 (de) * 1987-06-22 2001-11-15 Medeva Holdings Bv Hepatitis-b-oberflächenantigen enthaltendes peptid
IL89991A0 (en) * 1988-04-25 1989-12-15 Phillips Petroleum Co Expression of hepatitis b pres2 protein in methylotrophic yeasts
EP0345792A3 (fr) * 1988-06-10 1991-05-02 F. Hoffmann-La Roche Ag Protéines fusionnées HTLV-I/HIV-I
FR2635532B1 (fr) * 1988-07-29 1992-05-22 Pasteur Institut Particules hbsag recombinantes hybrides : caracteristiques morphologiques de l'antigene hbsag contenant 1 sequence immunogene induisant des anticorps neutralisants diriges contre hiv ou susceptible d'etre reconnue par de tels anticorps; sequences nucleotidiques codant pour de telles particules; vaccins les contenant
US5130247A (en) * 1989-09-19 1992-07-14 Merck & Co., Inc. Expression of fusion protein of HIV envelope and HBsAG
US5130248A (en) * 1989-09-19 1992-07-14 Merck & Co., Inc. Expression of fusion protein of HIV envelope and HBsAg
EP0421626A1 (fr) * 1989-09-19 1991-04-10 Merck & Co. Inc. Vaccin contre le SIDA et l'hépatite B
EP0491077A1 (fr) * 1990-12-19 1992-06-24 Medeva Holdings B.V. Composition utilisée comme agent thérapeutique contre des maladies hépatiques chroniques
DE69228698T2 (de) * 1991-11-16 1999-09-16 Smithkline Beecham Biologicals S.A., Rixensart HYBRIDES PROTEIN ZWISCHEN CS AUS PLASMODIUM UND HBsAG
WO1993013120A1 (fr) * 1991-12-23 1993-07-08 Chiron Corporation Sondes d'amplification de vhb utlisees dans des methodes d'hybridation en sandwich a phase en solution
US6297048B1 (en) 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
US5928902A (en) * 1992-02-27 1999-07-27 Smithkline Beecham Biologicals (S.A.) Hybrid protein between CS from plasmodium and HBsAg
US6169171B1 (en) 1992-02-27 2001-01-02 Smithkline Beecham Biologicals (S.A.) Hybrid protein between CS from plasmodium and HBSAG
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
AU671623B2 (en) * 1992-03-06 1996-09-05 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and biotinylated peptides used therein
US6667387B1 (en) 1996-09-30 2003-12-23 N.V. Innogenetics S.A. HCV core peptides
EP0565794A1 (fr) * 1992-04-14 1993-10-20 British Biotech Pharmaceuticals Limited Induction des réponses CTL
PT835663E (pt) 1992-05-23 2010-01-04 Glaxosmithkline Biolog Sa Vacinas combinadas compreendendo o antigénio de superfície da hepatite b e outros antigénios
CN1063343C (zh) * 1993-04-27 2001-03-21 中国科学院上海生物化学研究所 氨端带前表面抗原决定簇的乙型肝炎表面抗原蛋白
US6235888B1 (en) 1994-10-05 2001-05-22 The General Hospital Corporation Hepatitis C virus vaccine
RU2189254C2 (ru) * 1995-06-06 2002-09-20 Америкэн Хоум Продактс Корпорэйшн Вакцины против вирусов гепатита
JP4383530B2 (ja) 1996-04-05 2009-12-16 ノバルティス バクシンズ アンド ダイアグノスティックス， インコーポレーテッド 細胞巨大分子合成の阻害が減少したアルファウイルスベクター
CA2266656A1 (fr) 1996-09-17 1998-03-26 Chiron Corporation Compositions et procedes de traitement de maladies intracellulaires
GB9623233D0 (en) 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
CA2773698C (fr) 1998-10-16 2015-05-19 Glaxosmithkline Biologicals S.A. Systemes d'adjuvants comprenant un immunostimulant absorbe sur une part cule de sel metallique et vaccins derives
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
CN100381171C (zh) * 2004-12-30 2008-04-16 成都生物制品研究所 含前s1、前s2和s抗原决定簇的乙肝表面抗原复合颗粒
CN102675430B (zh) * 2005-08-12 2014-08-27 上海贺普药业股份有限公司 乙型肝炎病毒表面l蛋白相关肽
BRPI0708912B8 (pt) 2006-03-14 2021-07-27 Univ Oregon Health & Science métodos in vitro para detecção de mycobacterium tuberculosis e de células t expressando cd8 que especificamente reconhecem seq id no: 11 em um indivíduo
MX2009002560A (es) 2006-09-07 2009-03-20 Glaxosmithkline Biolog Sa Vacuna.
KR100836745B1 (ko) * 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
EP2444410A3 (fr) 2007-02-28 2012-08-08 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Polypeptides brachyury et procédés d'utilisation
EA201490303A1 (ru) 2007-05-02 2014-05-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
EP2293813A4 (fr) 2008-05-23 2012-07-11 Univ Michigan Vaccins à nanoémulsion
WO2010099472A2 (fr) 2009-02-27 2010-09-02 The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services Polypeptides spanx-b et leur utilisation
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
WO2014043518A1 (fr) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protéine brachyury, vecteurs non levure, non poxvirus, codant pour la protéine brachyury, et leur utilisation
EP3331554B1 (fr) 2015-08-03 2022-05-11 The U.S.A. as represented by the Secretary, Department of Health and Human Services Mutants de délétion de la protéine brachyury, vecteurs sans levure codant pour les mutants de délétion de la protéine brachyury, et leur utilisation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2145092B (en) * 1983-01-28 1988-04-07 Univ New York Protective peptide antigen
AU584580B2 (en) * 1982-09-08 1989-06-01 Smith Kline - Rit Hepatitis B virus vaccine
DE3585578D1 (de) * 1984-06-18 1992-04-16 Chiron Corp Hepatitisoberflaechenantigenpartikelvakzin.
EP0401941A3 (fr) * 1984-07-11 1991-04-17 Takeda Chemical Industries, Ltd. Antigène de surface du virus de l'hépatite B, et sa production
GB8421282D0 (en) * 1984-08-22 1984-09-26 Connaught Lab Multispecific antigenic proteins
EP0175261B1 (fr) * 1984-09-12 1991-12-11 Chiron Corporation Immunogènes à base de particule hybride
EP0180012A1 (fr) * 1984-10-27 1986-05-07 Wolfram H. Prof. Dr. Gerlich Séquence de polypeptide immunogène du virus de l'hépatite B
CN86100979A (zh) * 1985-02-07 1986-12-17 史密丝克莱恩贝克曼公司 疟疾疫苗的制备方法
US4774175A (en) * 1985-03-01 1988-09-27 Centocor, Inc. Immunochemical methods for the detection of antibody against HTLV-III
US4683294A (en) * 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
WO1986006077A1 (fr) * 1985-04-08 1986-10-23 Amgen Procede et activeur hybride permettant de commander la transcription de genes exogenes
FR2581394B1 (fr) * 1985-05-02 1988-08-05 Grp Genie Genetique Particules ayant les proprietes immunogenes de l'antigene hbs et portant un site antigenique etranger aux epitopes portes par l'antigene hbs, vecteurs et cellules animales pour la production de telles particules et compositions contenant de telles particules pour la production de vaccins mixtes
US4816564A (en) * 1986-01-31 1989-03-28 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
CA1310602C (fr) * 1986-06-03 1992-11-24 Hajime Horii Promoteur de la levure et procede pour la preparation de proteines heterologues

Also Published As

Publication number Publication date
YU17488A (en) 1991-02-28
AU1093088A (en) 1988-08-04
TNSN88004A1 (fr) 1990-07-10
FI880428A (fi) 1988-09-13
EP0278940A2 (fr) 1988-08-17
SU1746887A3 (ru) 1992-07-07
DK43188D0 (da) 1988-01-28
IL85216A0 (en) 1988-07-31
OA08801A (fr) 1989-03-31
FI880428A0 (fi) 1988-01-29
PT86640A (pt) 1988-02-01
EP0278940A3 (fr) 1988-12-07
PT86640B (pt) 1992-01-31
NO880395L (no) 1988-08-01
MA21169A1 (fr) 1988-10-01
NZ223297A (en) 1991-06-25
HUT50876A (en) 1990-03-28
AP56A (en) 1989-09-26
DD284899A5 (de) 1990-11-28
DK43188A (da) 1988-07-31
NO880395D0 (no) 1988-01-29
JPS6463382A (en) 1989-03-09
KR880009130A (ko) 1988-09-14
DD285994A5 (de) 1991-01-10
AP8800078A0 (en) 1987-11-01
CN1031395A (zh) 1989-03-01
DD285612A5 (de) 1990-12-19

Similar Documents

Publication Publication Date Title
AP8800078A0 (en) Hepatitis b virus surface antigens and hybrid antigens containing them
HK38293A (en) Hepatitis c virus
CY2614B2 (en) Combined vaccines comprising Hepatitis B surface and other antigens
SG102092G (en) Hepatitis c virus
PT85137A (en) T and b cell epitopes of the pre-s region of hepatitis b virus surface antigen
GB8816233D0 (en) Rubella e1 glycoprotein antigens
IL79740A0 (en) Hepatitis vaccine
ZA838856B (en) Hepatitis b and non-a-non-b-safe biological products
NZ224862A (en) Taenia ovis antigens and vaccines
GB2181434A (en) Hepatitis b virus vaccine and process for its preparation
GB8621578D0 (en) Hepatitis b viral antigens
GB8622883D0 (en) Expression of hepatitis b viral antigens
IE871644L (en) T and b cell epitopes of the pre-s region of hepatitis b¹virus surface antigen
ZA874498B (en) T and b cell epitopes of the pre-s region of hepatitis b virus surface antigen
GB8708532D0 (en) Particulate hybrid hiv antigens
NZ223535A (en) Recombinant hbv surface antigens
IE820073L (en) Preparing hepatitis b surface antigen
GB8703864D0 (en) Bluetongue virus antigens
GB8709779D0 (en) Bluetongue virus antigens
IE852110L (en) Recombinant hepatitis antigen
IE861419L (en) Isolation of hepatitis b surface antigen
IE880242L (en) Hepatitis b virus antigens.
NZ215820A (en) Hepatitis b antigen formed by recombinant dna techniques
IE851705L (en) Hepatitis B Virus Surfact Antigen and Production Thereof
IE880458L (en) Virus antigen